Ernexa Therapeutics, Inc. (ERNA)
4.30
+0.14
(+3.24%)
USD |
NASDAQ |
Sep 14, 10:06
Ernexa Therapeutics PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| December 30, 2025 | 769883.4 |
| December 29, 2025 | 769883.4 |
| December 26, 2025 | 796204.2 |
| December 24, 2025 | 835685.4 |
| December 23, 2025 | 815944.8 |
| December 22, 2025 | 842265.6 |
| December 19, 2025 | 862006.2 |
| December 18, 2025 | 829105.2 |
| December 17, 2025 | 815944.8 |
| December 16, 2025 | 862006.2 |
| December 15, 2025 | 848845.8 |
| December 12, 2025 | 894907.2 |
| December 11, 2025 | 973869.6 |
| December 10, 2025 | 842265.6 |
| December 09, 2025 | 894907.2 |
| December 08, 2025 | 855426.0 |
| December 05, 2025 | 868586.4 |
| December 04, 2025 | 862006.2 |
| December 03, 2025 | 756723.0 |
| December 02, 2025 | 789624.0 |
| December 01, 2025 | 822525.0 |
| November 28, 2025 | 888327.0 |
| November 26, 2025 | 908067.6 |
| November 25, 2025 | 888327.0 |
| November 24, 2025 | 848845.8 |
| Date | Value |
|---|---|
| November 21, 2025 | 888327.0 |
| November 20, 2025 | 842265.6 |
| November 19, 2025 | 914647.8 |
| November 18, 2025 | 973869.6 |
| November 17, 2025 | 993610.2 |
| November 14, 2025 | 1.000M |
| November 13, 2025 | 1.033M |
| November 12, 2025 | 1.059M |
| November 11, 2025 | 1.040M |
| November 10, 2025 | 1.099M |
| November 07, 2025 | 1.152M |
| November 06, 2025 | 1.112M |
| November 05, 2025 | 1.086M |
| November 04, 2025 | 1.105M |
| November 03, 2025 | 1.099M |
| October 31, 2025 | 1.237M |
| October 30, 2025 | 1.171M |
| October 29, 2025 | 1.158M |
| October 28, 2025 | 822525.0 |
| October 27, 2025 | 783043.8 |
| October 24, 2025 | 815944.8 |
| October 23, 2025 | 769883.4 |
| October 22, 2025 | 756723.0 |
| October 21, 2025 | 796204.2 |
| October 20, 2025 | 822064.4 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Cerenome, Inc. | 3.116 |
| ACADIA Pharmaceuticals, Inc. | 4.177 |
| Alnylam Pharmaceuticals, Inc. | 7.097 |
| Anika Therapeutics, Inc. | 2.435 |
| Savara, Inc. | -- |
PS Ratio Related Metrics
| Price to Book Value | 1.573 |
| Price | 4.30 |
| Earnings Yield | -440.1% |
| Market Cap | 5.031M |